The Directory of Pharma Companies and News
Pre-clinical proof of concept has been obtained with two different IgE antibodies both showing significantly greater efficacy versus IgG comparators in a variety of rodent cancer models. IGEM is building a portfolio of IgE antibody candidates targeting folate receptor alpha, HER2, EGFR, PD-L1 and CSPG4. The company is also developing a novel antibody platform technology based on protein and glyco-engineering of the epsilon constant region of IgE.
IGEM is a spin out of King’s College London and has access to the world class expertise in the lab of Dr Sophia Karagiannis at KCL.